Hospital
Mary Washington Hospital INC.
Mary Washington Hospital INC. was paid $80.25M by Medicaid between Jan 2018 and Dec 2024, across 392 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoMARY WASHINGTON HOSPITAL INC.
FREDERICKSBURG, VA 22401
FREDERICKSBURG, VA 22401
33aNPI1942288527assigned 01/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$80.25M
24GClaims2,016,585
24DCodes billed392
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#5 of 80
Median peer was paid$14.69M
This provider vs. median5.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official NEWMAN, CHRISTOPHER controls 16+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 184,577 | $5.68M | |
| 2019 | 304,174 | $9.91M | |
| 2020 | 270,148 | $9.68M | |
| 2021 | 309,258 | $10.52M | |
| 2022 | 308,591 | $11.75M | |
| 2023 | 352,314 | $16.48M | |
| 2024incomplete | 287,523 | $16.24M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 78,360 | 66,748 | $14.44M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 52,939 | 46,908 | $9.08M |
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 35,318 | 25,888 | $8.50M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.6% | 22,821 | 19,793 | $4.51M |
| G0378 | Hospital observation service, per hour | 5.0% | 16,415 | 13,147 | $4.00M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 4.2% | 13,887 | 3,335 | $3.36M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4.2% | 25,623 | 17,776 | $3.35M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.0% | 19,755 | 17,679 | $3.17M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.5% | 14,643 | 12,853 | $2.83M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.0% | 11,418 | 10,304 | $2.42M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.2% | 3,669 | 3,310 | $1.74M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.7% | 11,306 | 9,185 | $1.34M |
380 more codes
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.7% | 5,429 | $1.33M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.4% | 1,506 | $1.09M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 11,409 | $1.06M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.3% | 6,204 | $1.02M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 2,924 | $898K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.1% | 1,661 | $895K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 4,420 | $882K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.0% | 19,125 | $831K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 3,066 | $599K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 15,960 | $485K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 14,383 | $481K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,287 | $471K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,587 | $432K |
| 80053 | Comprehensive metabolic panel | <1% | 92,668 | $399K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,301 | $372K |
| 59025 | Fetal non-stress test | <1% | 2,155 | $358K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 5,182 | $330K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 5,256 | $329K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,781 | $323K |
| 29580 | <1% | 1,779 | $306K | |
| 93971 | <1% | 3,235 | $282K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 13,746 | $260K |
| 97161 | <1% | 2,253 | $254K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,485 | $230K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,306 | $220K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 4,382 | $210K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,197 | $203K |
| 93017 | <1% | 1,959 | $203K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,456 | $203K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,279 | $192K |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 5,110 | $189K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,846 | $188K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 962 | $187K |
| 70496 | <1% | 686 | $183K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 8,771 | $172K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 707 | $169K |
| 97602 | <1% | 1,026 | $169K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,213 | $168K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 224 | $165K |
| 12001 | <1% | 729 | $161K | |
| 93458 | <1% | 105 | $151K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 143 | $130K |
| 36430 | <1% | 768 | $130K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 13,778 | $129K |
| 76801 | <1% | 2,879 | $123K | |
| 87400 | <1% | 9,097 | $119K | |
| 93970 | <1% | 1,109 | $118K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 274 | $116K |
| 29125 | <1% | 915 | $111K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,815 | $108K |
| 80329 | <1% | 8,323 | $104K | |
| 97162 | <1% | 701 | $94K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 1,034 | $92K |
| 83880 | <1% | 9,469 | $83K | |
| 97116 | <1% | 3,090 | $83K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 8,657 | $79K |
| 92523 | <1% | 308 | $77K | |
| 12011 | <1% | 334 | $75K | |
| 87040 | <1% | 7,514 | $75K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 94,736 | $70K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,017 | $69K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 1,751 | $67K |
| 70498 | <1% | 1,055 | $66K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 383 | $66K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 34,756 | $65K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 19,554 | $63K |
| 10060 | <1% | 440 | $60K | |
| 93000 | <1% | 33,415 | $60K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,038 | $56K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 13,662 | $56K |
| 96367 | <1% | 2,410 | $53K | |
| 95816 | <1% | 275 | $53K | |
| 76818 | <1% | 1,370 | $50K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,631 | $49K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 373 | $48K |
| 84484 | <1% | 32,993 | $47K | |
| 71250 | <1% | 554 | $44K | |
| 85379 | <1% | 8,537 | $44K | |
| 93798 | <1% | 246 | $43K | |
| 71045 | Radiologic examination, chest; single view | <1% | 26,484 | $41K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 141 | $41K |
| 76770 | <1% | 379 | $40K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 9,172 | $37K |
| 95811 | <1% | 62 | $37K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,992 | $37K |
| 29515 | <1% | 313 | $36K | |
| 73564 | <1% | 4,086 | $35K | |
| 12002 | <1% | 177 | $34K | |
| 97016 | <1% | 1,102 | $34K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,982 | $32K |
| 87653 | <1% | 1,095 | $27K | |
| 70486 | <1% | 748 | $27K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,284 | $26K |
| 80061 | Lipid panel | <1% | 8,142 | $23K |
| 77295 | <1% | 16 | $23K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,751 | $22K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,879 | $20K |
| 83735 | <1% | 43,352 | $20K | |
| 77336 | <1% | 277 | $20K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 7,028 | $19K |
| 87070 | <1% | 4,189 | $19K | |
| 72110 | <1% | 2,190 | $18K | |
| 80320 | <1% | 10,387 | $17K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 41 | $16K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 11,543 | $16K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,602 | $16K |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,157 | $16K |
| 90714 | <1% | 742 | $16K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 101 | $15K |
| 62323 | <1% | 18 | $15K | |
| 83605 | <1% | 9,864 | $15K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 45 | $14K |
| 88304 | <1% | 1,166 | $14K | |
| 70491 | <1% | 70 | $14K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,486 | $13K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 20,189 | $13K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 29,424 | $13K |
| A9270 | Non-covered item or service | <1% | 212,648 | $12K |
| 86140 | <1% | 4,105 | $12K | |
| 74018 | <1% | 3,979 | $12K | |
| 87428 | <1% | 13,151 | $12K | |
| 95800 | <1% | 72 | $12K | |
| 76813 | <1% | 143 | $12K | |
| 73030 | <1% | 2,878 | $11K | |
| 84702 | <1% | 4,583 | $11K | |
| 72100 | <1% | 2,633 | $11K | |
| 97605 | <1% | 52 | $11K | |
| 80306 | <1% | 10,717 | $10K | |
| 72050 | <1% | 1,232 | $10K | |
| 88342 | <1% | 2,012 | $10K | |
| 81001 | <1% | 34,141 | $10K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 8,939 | $9K |
| 84703 | <1% | 21,236 | $9K | |
| 84439 | <1% | 2,393 | $9K | |
| 97802 | <1% | 64 | $9K | |
| J3490 | Unclassified drugs | <1% | 18,357 | $9K |
| 82728 | <1% | 2,480 | $9K | |
| 85027 | <1% | 8,600 | $8K | |
| 76820 | <1% | 501 | $8K | |
| 86923 | <1% | 478 | $8K | |
| 43248 | <1% | 24 | $8K | |
| 82607 | <1% | 2,713 | $8K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 158 | $7K |
| 82948 | <1% | 27,837 | $7K | |
| 90686 | <1% | 490 | $7K | |
| 83690 | <1% | 26,419 | $7K | |
| 86780 | <1% | 1,312 | $7K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 43 | $7K |
| 85610 | <1% | 22,032 | $7K | |
| 84145 | <1% | 793 | $6K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,155 | $6K |
| 73630 | <1% | 3,427 | $6K | |
| 73610 | <1% | 3,227 | $6K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 213 | $6K |
| 76870 | <1% | 91 | $6K | |
| 72072 | <1% | 1,376 | $6K | |
| 20610 | <1% | 26 | $6K | |
| 87510 | <1% | 590 | $6K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 174 | $6K |
| 73130 | <1% | 2,564 | $6K | |
| 90715 | <1% | 266 | $6K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 18 | $5K |
| 29581 | <1% | 33 | $5K | |
| 95819 | <1% | 30 | $5K | |
| 86850 | <1% | 5,641 | $5K | |
| 86900 | <1% | 9,031 | $5K | |
| 87641 | <1% | 351 | $5K | |
| 73502 | <1% | 1,641 | $5K | |
| 87205 | <1% | 3,430 | $5K | |
| 20552 | <1% | 14 | $5K | |
| 82550 | <1% | 3,728 | $5K | |
| 87186 | <1% | 5,425 | $5K | |
| 85007 | <1% | 6,040 | $5K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 203 | $4K |
| 75574 | <1% | 27 | $4K | |
| 96376 | <1% | 14,541 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 27,404 | $4K |
| 81003 | <1% | 24,644 | $4K | |
| 87480 | <1% | 590 | $4K | |
| 87147 | <1% | 2,301 | $4K | |
| 99495 | <1% | 28 | $3K | |
| 87660 | <1% | 595 | $3K | |
| 73110 | <1% | 1,825 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 21,294 | $3K |
| 86901 | <1% | 9,027 | $3K | |
| 82247 | <1% | 670 | $3K | |
| 83550 | <1% | 2,073 | $3K | |
| 97167 | <1% | 13 | $3K | |
| 83970 | <1% | 285 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 11,579 | $3K |
| 93880 | <1% | 75 | $3K | |
| 82570 | <1% | 2,166 | $3K | |
| 85014 | <1% | 2,052 | $3K | |
| 88142 | <1% | 179 | $3K | |
| 83540 | <1% | 2,257 | $3K | |
| 77334 | <1% | 31 | $3K | |
| 90656 | <1% | 74 | $3K | |
| 87088 | <1% | 4,519 | $3K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 871 | $3K |
| 81025 | <1% | 8,179 | $2K | |
| 72040 | <1% | 393 | $2K | |
| 77300 | <1% | 23 | $2K | |
| 97165 | <1% | 49 | $2K | |
| 84100 | <1% | 2,865 | $2K | |
| 85651 | <1% | 1,967 | $2K | |
| 0352U | <1% | 354 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 157 | $2K |
| 85652 | <1% | 1,824 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 91 | $2K |
| 87807 | <1% | 5,111 | $2K | |
| 86803 | <1% | 541 | $2K | |
| 82746 | <1% | 1,605 | $2K | |
| 97166 | <1% | 27 | $2K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 17 | $2K |
| 77280 | <1% | 21 | $2K | |
| 82947 | <1% | 2,421 | $2K | |
| 73590 | <1% | 1,344 | $2K | |
| 80074 | <1% | 233 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,639 | $1K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 15 | $1K |
| 85018 | <1% | 3,110 | $1K | |
| 88173 | <1% | 126 | $1K | |
| 82330 | <1% | 2,643 | $1K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,735 | $1K |
| 84132 | <1% | 2,751 | $1K | |
| 87077 | <1% | 1,062 | $1K | |
| 82248 | <1% | 931 | $1K | |
| 87340 | <1% | 900 | $1K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,337 | $1K |
| 87081 | <1% | 293 | $1K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 84 | $1K |
| 82565 | <1% | 4,109 | $1K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 173 | $1K |
| 73090 | <1% | 918 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 12,811 | $1K |
| 87210 | <1% | 2,687 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,032 | $1K |
| 73080 | <1% | 627 | $984.04 | |
| 85730 | <1% | 3,485 | $979.63 | |
| 80202 | <1% | 91 | $869.75 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 10,491 | $867.34 |
| 80051 | <1% | 568 | $853.32 | |
| 83615 | <1% | 895 | $801.46 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 1,552 | $791.50 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 9,232 | $783.35 |
| 86308 | <1% | 2,481 | $748.52 | |
| 86625 | <1% | 166 | $747.38 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 162 | $729.10 |
| 71101 | <1% | 582 | $705.04 | |
| 82043 | <1% | 646 | $681.59 | |
| 84156 | <1% | 953 | $676.28 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,795 | $599.39 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,238 | $591.20 |
| 88141 | <1% | 36 | $566.03 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,473 | $556.34 |
| 74022 | <1% | 157 | $555.20 | |
| 88341 | <1% | 68 | $551.64 | |
| J2704 | Injection, propofol, 10 mg | <1% | 10,752 | $526.49 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,263 | $510.11 |
| 82803 | <1% | 2,077 | $509.84 | |
| 86706 | <1% | 150 | $498.05 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 356 | $491.49 |
| 99152 | <1% | 1,120 | $484.68 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 5,444 | $478.56 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 794 | $474.41 |
| 84520 | <1% | 181 | $465.70 | |
| 88172 | <1% | 12 | $456.50 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,555 | $436.39 |
| 86480 | <1% | 14 | $423.47 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 36 | $402.64 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,678 | $398.83 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,818 | $397.99 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,229 | $397.64 |
| 80164 | <1% | 53 | $389.21 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,804 | $360.41 |
| 87899 | <1% | 616 | $345.07 | |
| 94644 | <1% | 199 | $327.43 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,816 | $325.42 |
| 87116 | <1% | 16 | $317.52 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 3,342 | $307.58 |
| 73140 | <1% | 543 | $304.59 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,441 | $298.80 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,379 | $294.95 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 38 | $283.99 |
| 88307 | <1% | 12 | $273.57 | |
| 84550 | <1% | 572 | $260.82 | |
| 86703 | <1% | 117 | $240.56 | |
| 36600 | <1% | 164 | $228.63 | |
| 70360 | <1% | 76 | $225.78 | |
| 72170 | <1% | 188 | $213.24 | |
| 86762 | <1% | 63 | $203.87 | |
| J7070 | Infusion, d5w, 1000 cc | <1% | 1,731 | $202.46 |
| 73060 | <1% | 87 | $202.15 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,016 | $199.94 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 2,367 | $195.25 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 27 | $187.79 |
| 73552 | <1% | 155 | $160.54 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 734 | $159.77 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 238 | $159.03 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 25 | $157.58 |
| 84295 | <1% | 719 | $154.37 | |
| 73560 | <1% | 15 | $150.52 | |
| 87045 | <1% | 182 | $146.81 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,572 | $145.77 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 248 | $122.28 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,781 | $112.49 |
| C1769 | Guide wire | <1% | 769 | $91.41 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 942 | $86.33 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 4,018 | $85.49 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,088 | $83.16 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 933 | $81.27 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 816 | $79.04 |
| 87102 | <1% | 48 | $73.71 | |
| 87181 | <1% | 74 | $69.05 | |
| 85384 | <1% | 170 | $66.36 | |
| 94664 | <1% | 391 | $60.65 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 464 | $57.92 |
| 81015 | <1% | 544 | $55.54 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 886 | $53.56 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 799 | $48.04 |
| 87075 | <1% | 20 | $46.26 | |
| 86038 | <1% | 12 | $46.20 | |
| 89051 | <1% | 37 | $37.13 | |
| 36416 | <1% | 40 | $35.25 | |
| 84481 | <1% | 17 | $34.52 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 263 | $33.58 |
| 73070 | <1% | 27 | $30.54 | |
| 98960 | <1% | 18 | $29.91 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 133 | $28.48 |
| 87450 | <1% | 15 | $28.45 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 251 | $28.31 |
| 82150 | <1% | 15 | $24.52 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 270 | $23.69 |
| 87449 | <1% | 30 | $23.60 | |
| 87015 | <1% | 38 | $23.12 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 234 | $18.05 |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | <1% | 29 | $15.34 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 618 | $14.61 |
| 85008 | <1% | 212 | $11.00 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 50 | $9.42 |
| 87324 | <1% | 12 | $8.51 | |
| 82435 | <1% | 85 | $7.71 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 325 | $7.70 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 226 | $6.75 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 40 | $6.04 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 50 | $5.70 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 74 | $4.50 |
| J1815 | Injection, insulin, per 5 units | <1% | 36 | $4.04 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 49 | $3.68 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 14 | $2.88 |
| J3410 | Injection, hydroxyzine hcl, up to 25 mg | <1% | 20 | $1.25 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 874 | $1.06 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 19 | $0.46 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 195 | $0.25 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 306 | $0.15 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 275 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 97 | $0.00 |
| A4217 | Sterile water/saline, 500 ml | 0% | 21 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 53 | $0.00 |
| 73660 | 0% | 13 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 14 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 14 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 77 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 216 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 34 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 142 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 119 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 156 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 96 | $0.00 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 72 | $0.00 |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | 0% | 43 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 44 | $0.00 |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 0% | 114 | $0.00 |
| 76937 | 0% | 12 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 22 | $0.00 |
| 51702 | 0% | 119 | $0.00 | |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 71 | $0.00 |
| 85347 | 0% | 19 | $0.00 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 17 | $0.00 |
| 93325 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNEWMAN, CHRISTOPHER (CEO)
| Provider | Location | Paid |
|---|---|---|
| Stafford Hospital, LLC | Stafford, VA | $25.29M |
| Mary Washington Healthcare Physicians | Fredericksburg, VA | $13.36M |
| Camelback Recovery Treatment Center | Phoenix, AZ | $2.96M |
| Mary Washington Healthcare Providers LLC | Fredericksburg, VA | $2.50M |
| Mary Washington Hospital, INC. | Fredericksburg, VA | $1.78M |
| MWHC Urgent Care LLC | King George, VA | $792K |
| MWHC Urgent Care LLC | Stafford, VA | $536K |
| Mary Washington Hospital, INC. | Fredericksburg, VA | $394K |
| Mary Washington Eye Care Center, LLC | Fredericksburg, VA | $375K |
| MWHC Urgent Care LLC | Fredericksburg, VA | $91K |
| Mary Washington Healthcare Specialty Services LLC | Fredericksburg, VA | $69K |
| Mary Washington Healthcare Clinical Services, INC. | Fredericksburg, VA | $65K |
| Camelback Physicians Group LLC | Phoenix, AZ | $52K |
| Fredericksburg Ambulatory Surgery Center, LLC | Fredericksburg, VA | $20K |
| MWHC Urgent Care LLC | Stafford, VA | $14K |
| Stafford Hospital, LLC | Stafford, VA | $11.96 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.